Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes
{{output}}
Background: Limited evidence exists to support the simultaneous initiation of sodium-glucose cotransporter-2 inhibitors and finerenone, a nonsteroidal mineralocorticoid receptor antagonist, in persons with chronic kidney disease ... ...
